Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Jan. 24, 1:46 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #9 of 100 |
Slide #9. Celgene Corporation — Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders
Acquirer:
Celgene Corporation (CELG)
Acquiree:
Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders
Details:
Celgene Corporation (NASDAQ:CELG) entered into a global license agreement with Nogra Pharma Limited, a private pharmaceutical company based in Dublin, Ireland, to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn's disease and other indications.
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold primarily to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics and government agencies. Co. manufactures products in the U.S. and Puerto Rico and has manufacturing operations in several foreign countries. Co. has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics.
Open the CELG Page at The Online Investor »
|
||||||||||||
Open the CELG Page at The Online Investor (in a new window) »
 Free CELG Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
